NASDAQ:GLTO Galecto (GLTO) Stock Forecast, Price & News $2.39 +0.13 (+5.75%) (As of 06/6/2023 ET) Add Compare Share Share Today's Range$2.26▼$2.4150-Day Range$1.68▼$2.6652-Week Range$1.04▼$2.95Volume57,183 shsAverage Volume61,502 shsMarket Capitalization$61.35 millionP/E RatioN/ADividend YieldN/APrice Target$11.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Galecto MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside388.1% Upside$11.67 Price TargetShort InterestHealthy0.07% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$401,514 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.30) to ($2.32) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.10 out of 5 starsMedical Sector414th out of 981 stocksPharmaceutical Preparations Industry199th out of 460 stocks 3.5 Analyst's Opinion Consensus RatingGalecto has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.67, Galecto has a forecasted upside of 388.1% from its current price of $2.39.Amount of Analyst CoverageGalecto has only been the subject of 3 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.07% of the float of Galecto has been sold short.Short Interest Ratio / Days to CoverGalecto has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Galecto has recently decreased by 3.28%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldGalecto does not currently pay a dividend.Dividend GrowthGalecto does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GLTO. Previous Next 1.5 News and Social Media Coverage News SentimentGalecto has a news sentiment score of -0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.Search InterestOnly 1 people have searched for GLTO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows3 people have added Galecto to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Galecto insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $401,514.00 in company stock.Percentage Held by Insiders12.10% of the stock of Galecto is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 35.82% of the stock of Galecto is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Galecto are expected to decrease in the coming year, from ($2.30) to ($2.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Galecto is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Galecto is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGalecto has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Galecto (NASDAQ:GLTO) StockGalecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.Read More Receive GLTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galecto and its competitors with MarketBeat's FREE daily newsletter. Email Address GLTO Stock News HeadlinesMay 30, 2023 | finance.yahoo.comGalecto to Present at the Upcoming Jefferies Healthcare ConferenceMay 25, 2023 | americanbankingnews.comGalecto, Inc. (NASDAQ:GLTO) Expected to Earn Q1 2024 Earnings of ($0.36) Per ShareJune 6, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 24, 2023 | msn.comHC Wainwright & Co. Reiterates Galecto (GLTO) Buy RecommendationMay 24, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Galecto (GLTO), Bioxcel Therapeutics (BTAI) and Wave Life Sciences (WVE)May 23, 2023 | finance.yahoo.comGalecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary FibrosisMay 20, 2023 | finance.yahoo.comCompanies Like Galecto (NASDAQ:GLTO) Could Be Quite RiskyMay 17, 2023 | finance.yahoo.comGalecto to Present Poster at Upcoming ATS 2023 International ConferenceJune 6, 2023 | MarketBeat Internal (Ad)Save $200 on MarketBeat All AccessMarketBeat All Access is the premier all-in-one stock research solution that helps you identify the best stocks, monitor your portfolio, and keep track of the market. You get our top stock picks, best-in-class research tools, real-time alerts, proprietary research reports and much more. Claim your $200 account credit and free 30-day trial subscription today.May 17, 2023 | americanbankingnews.comGalecto, Inc. (NASDAQ:GLTO) Forecasted to Post Q2 2023 Earnings of ($0.59) Per ShareMay 16, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of Galecto (GLTO) with Buy RecommendationMay 15, 2023 | markets.businessinsider.comGalecto (GLTO) Gets a Buy from H.C. WainwrightMay 15, 2023 | americanbankingnews.comGalecto (NASDAQ:GLTO) Earns Buy Rating from Analysts at HC WainwrightApril 28, 2023 | finanznachrichten.deGalecto, Inc.: Galecto Reports First Quarter Operating and Financial ResultsApril 20, 2023 | americanbankingnews.comOrbimed Advisors Llc Sells 13,089 Shares of Galecto, Inc. (NASDAQ:GLTO) StockApril 19, 2023 | americanbankingnews.comOrbimed Advisors Llc Sells 41,446 Shares of Galecto, Inc. (NASDAQ:GLTO) StockApril 13, 2023 | finance.yahoo.comGalecto to Present Two Posters at AACR Annual Meeting 2023April 13, 2023 | americanbankingnews.comGalecto, Inc. (NASDAQ:GLTO) Major Shareholder Sells $91,698.12 in StockApril 10, 2023 | 247wallst.comOrbimed Advisors Now Owns 10.5% of GalectoApril 8, 2023 | americanbankingnews.comGalecto, Inc. (NASDAQ:GLTO) Major Shareholder Orbimed Advisors Llc Sells 92,965 SharesMarch 21, 2023 | americanbankingnews.comGalecto (NASDAQ:GLTO) Receives New Coverage from Analysts at Cantor FitzgeraldMarch 20, 2023 | nasdaq.comCantor Fitzgerald Initiates Coverage of Galecto (GLTO) with Overweight RecommendationMarch 9, 2023 | finance.yahoo.comGalecto Reports Operating and Financial Results for the Year Ended December 31, 2022March 4, 2023 | benzinga.comGalecto to Participate in Oppenheimer's 33rd Annual Healthcare ConferenceMarch 2, 2023 | finance.yahoo.comGalecto to Participate in Oppenheimer’s 33rd Annual Healthcare ConferenceFebruary 24, 2023 | nz.finance.yahoo.comGalecto, Inc. (GLTO) stock price, news, quote & history – Yahoo FinanceFebruary 1, 2023 | finance.yahoo.comGalecto to Participate in SVB Securities Global Biopharma ConferenceSee More Headlines GLTO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GLTO Company Calendar Last Earnings3/09/2023Today6/06/2023Next Earnings (Estimated)8/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GLTO CUSIPN/A CIK1800315 Webgalecto.com Phone45-7070-5210FaxN/AEmployees28Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.67 High Stock Price Forecast$16.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+388.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-61,620,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-85.49% Return on Assets-73.78% Debt Debt-to-Equity RatioN/A Current Ratio4.06 Quick Ratio4.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.41 per share Price / Book0.99Miscellaneous Outstanding Shares25,670,000Free Float22,567,000Market Cap$61.35 million OptionableNot Optionable Beta0.74 Key ExecutivesDr. Hans T. Schambye M.D. (Age 56)Ph.D., Co-Founder, Pres, CEO & Director Comp: $735.2kMr. Jonathan P. Freve CPA (Age 44)CPA, Chief Financial Officer Comp: $602.4kMr. Anders Pedersen (Age 62)Chief Operating Officer Comp: $540.39kMr. Ulf J. NilssonCo-FounderDr. Hakon LefflerCo-FounderProf. Tariq Sethi M.D.B.Sc., M.A., Ph.D., FRCP, Co-Founder & Member of the Clinical Advisory Board - IPFMr. Garrett Winslow Esq. (Age 43)Sr. VP, Gen. Counsel & Corp. Sec. Prof. Bertil Lindmark M.D. (Age 67)Ph.D., Chief Medical Officer Dr. Stephanie Oestreich Ph.D. (Age 48)Chief Bus. Officer More ExecutivesKey CompetitorsLifeVantageNASDAQ:LFVNLantern PharmaNASDAQ:LTRNIO BiotechNASDAQ:IOBTAbeona TherapeuticsNASDAQ:ABEOAdageneNASDAQ:ADAGView All CompetitorsInsiders & InstitutionsSusquehanna International Group LLPBought 15,016 shares on 5/16/2023Ownership: 0.246%Two Sigma Advisers LPSold 9,000 shares on 5/15/2023Ownership: 0.209%MAI Capital ManagementBought 22,170 shares on 5/10/2023Ownership: 0.995%Orbimed Advisors LlcSold 13,089 sharesTotal: $25,785.33 ($1.97/share)Orbimed Advisors LlcSold 41,446 sharesTotal: $77,089.56 ($1.86/share)View All Insider TransactionsView All Institutional Transactions GLTO Stock - Frequently Asked Questions Should I buy or sell Galecto stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Galecto in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GLTO shares. View GLTO analyst ratings or view top-rated stocks. What is Galecto's stock price forecast for 2023? 4 analysts have issued 12 month price targets for Galecto's stock. Their GLTO share price forecasts range from $6.00 to $16.00. On average, they expect the company's share price to reach $11.67 in the next year. This suggests a possible upside of 388.1% from the stock's current price. View analysts price targets for GLTO or view top-rated stocks among Wall Street analysts. How have GLTO shares performed in 2023? Galecto's stock was trading at $1.15 on January 1st, 2023. Since then, GLTO stock has increased by 107.8% and is now trading at $2.39. View the best growth stocks for 2023 here. When is Galecto's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023. View our GLTO earnings forecast. How were Galecto's earnings last quarter? Galecto, Inc. (NASDAQ:GLTO) announced its quarterly earnings results on Thursday, March, 9th. The company reported ($0.55) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.02. What ETF holds Galecto's stock ? BlackRock Future Health ETF holds 610 shares of GLTO stock, representing 0.02% of its portfolio. When did Galecto IPO? (GLTO) raised $86 million in an initial public offering (IPO) on Thursday, October 29th 2020. The company issued 5,700,000 shares at $14.00-$16.00 per share. BofA Securities, SVB Leerink and Credit Suisse served as the underwriters for the IPO and Kempen & Co. was co-manager. What is Galecto's stock symbol? Galecto trades on the NASDAQ under the ticker symbol "GLTO." Who are Galecto's major shareholders? Galecto's stock is owned by a variety of retail and institutional investors. Top institutional investors include MAI Capital Management (1.00%), Susquehanna International Group LLP (0.25%) and Two Sigma Advisers LP (0.21%). Insiders that own company stock include Bertil Lindmark, Garrett Winslow, Hans T Schambye, Jonathan Freve and Orbimed Advisors Llc. View institutional ownership trends. How do I buy shares of Galecto? Shares of GLTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Galecto's stock price today? One share of GLTO stock can currently be purchased for approximately $2.39. How much money does Galecto make? Galecto (NASDAQ:GLTO) has a market capitalization of $61.35 million. The company earns $-61,620,000.00 in net income (profit) each year or ($2.27) on an earnings per share basis. How can I contact Galecto? Galecto's mailing address is GALECTO BIOTECH AB OLE MAALOES VEJ3, COPENHAGEN G7, DK-2200. The official website for the company is galecto.com. The company can be reached via phone at 45-7070-5210. This page (NASDAQ:GLTO) was last updated on 6/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galecto, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.